Orchard Therapeutics plc (NASDAQ:ORTX) shares traded 3.22% higher at $0.57 on Wall Street last session.
In accordance with the data, 6 analysts cover Orchard Therapeutics plc (NASDAQ:ORTX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $1.00, we find $3.00. Given the previous closing price of $0.55, this indicates a potential upside of 445.45 percent. ORTX stock price is now 6.58% away from the 50-day moving average and 10.28% away from the 200-day moving average. The market capitalization of the company currently stands at $72.26M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
It has been rated a hold by 2 analysts and a buy by 4. Brokers who have rated the stock have averaged $3.00 as their price target over the next twelve months.
, while the JP Morgan previously rated the stock as ‘Neutral’ on August 18, 2021.
In other news, Gaspar Bobby, Chief Executive Officer bought 15,000 shares of the company’s stock on Apr 01. The stock was bought for $11,085 at an average price of $0.74. Upon completion of the transaction, the Chief Executive Officer now directly owns 366,158 shares in the company, valued at $0.21 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 01, See Remarks THOMAS FRANK E bought 10,000 shares of the business’s stock. A total of $7,474 was incurred on buying the stock at an average price of $0.75. This leaves the insider owning 52,081 shares of the company worth $29686.17. A total of 7.68% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ORTX stock. A new stake in Orchard Therapeutics plc shares was purchased by MARINER, LLC during the first quarter worth $358,000. STRATEGIC WEALTH ADVISORS GROUP, LLC invested $294,000 in shares of ORTX during the first quarter. In the first quarter, GOLDMAN SACHS GROUP INC acquired a new stake in Orchard Therapeutics plc valued at approximately $11,000. VIRTU FINANCIAL LLC acquired a new stake in ORTX for approximately $7,000. LANE GENERATIONAL LLC purchased a new stake in ORTX valued at around $6,000 in the second quarter. In total, there are 61 active investors with 42.50% ownership of the company’s stock.
Orchard Therapeutics plc (NASDAQ: ORTX) opened at $0.5800 on Tuesday. During the past 12 months, Orchard Therapeutics plc has had a low of $0.36 and a high of $0.89. As of last week, the company has a debt-to-equity ratio of 0.27, a current ratio of 3.60, and a quick ratio of 3.50. The fifty day moving average price for ORTX is $0.5334 and a two-hundred day moving average price translates $0.5153 for the stock.
The latest earnings results from Orchard Therapeutics plc (NASDAQ: ORTX) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.37, missing analysts’ expectations of -$0.24 by -0.13. This compares to -$0.29 EPS in the same period last year. The company reported revenue of $5.78 million for the quarter, compared to $1.19 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 384.65 percent. For the current quarter, analysts expect ORTX to generate $4.95M in revenue.
Orchard Therapeutics plc(ORTX) Company Profile
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified cellular drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
